U.K. Tests World-First Personalized Skin Cancer Vaccine [Forbes]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Forbes
British patients are trying a first-of-its-kind customized vaccine for skin cancer as part of a international trial. The shots — which are tweaked for each participant — are “one of the most exciting developments in modern cancer therapy,” one specialist said. Personalized with genetic information from a patient's own tumor, vaccines like this could one day be used against cancers in other parts of the body, including the bladder, the colon, the lungs and the kidneys. The mRNA shots from Moderna help train a patient's body to recognize and fight cancer cells. The hope is they'll stop the disease from returning. And they've already shown promise, significantly reducing the chance of melanoma coming back in patients involved in Molecular oncology professor Lawrence Young, who was not involved in the trial, said that “interest in cancer vaccines has been reignited in recent years” by a growing understanding of the workings of the immuny system and by advances in mRNA technolog
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Moderna, Inc. (NASDAQ: MRNA) had its price target raised by analysts at UBS Group AG from $143.00 to $151.00. They now have a "buy" rating on the stock.MarketBeat
- Prologue, Flagship's newest startup, looks to mine viruses for new drugs [Yahoo! Finance]Yahoo! Finance
- Elis: Q1 2024 revenue [Yahoo! Finance]Yahoo! Finance
- Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Analysts Are Updating Their Moderna, Inc. (NASDAQ:MRNA) Estimates After Its First-Quarter Results [Yahoo! Finance]Yahoo! Finance
MRNA
Earnings
- 5/2/24 - Beat
MRNA
Sec Filings
- 5/3/24 - Form 4
- 5/2/24 - Form 10-Q
- 5/2/24 - Form 8-K
- MRNA's page on the SEC website